SHP-77細(xì)胞
器官來源： 肺
運(yùn)輸方式： 凍存運(yùn)輸
數(shù)量： 大量
ATCC Number： CRL-2195?
相關(guān)**： 小細(xì)胞肺癌
年限： 54 years
細(xì)胞類型： 其他細(xì)胞類型
生長狀態(tài)： 懸浮生長
細(xì)胞形態(tài)： 上皮樣
是否是腫瘤細(xì)胞： 1
物種來源： 人
Designations: SHP-77
SHP-77細(xì)胞Depositors: AM Koros
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension and loosely adherent
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: lung
Disease: carcinoma; small cell lung cancer
Cell Type: large cell, variant;
Cellular Products: SHP-77細(xì)胞neural cell adhesion molecule (NCAM) NKH-1
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Antigen Expression: Blood Type O; Rh +; CD56; CD57 (HNK-1,Leu-7)
DNA Profile (STR): Amelogenin: X
CSF1PO: 10,11
D13S317: 8
D16S539: 11
D5S818: 12
D7S820: 11
THO1: 7
TPOX: 9,11
vWA: 16
Age: 54 years
Gender: male
Ethnicity: Caucasian
Comments: SHP-77細(xì)胞The SHP-77 (Shadyside Hospital, Pittsburgh, PA) cell line is a biochemically stable continuously cultured cell line which has retained important features of SCLC.
It was established in 1977 by Edwin R. Fisher and John D. Paulson.
The line was derived from a non-encapsulated primary lung tumor from the apical portion of the upper lobe of the left lung.
This cell line is an unusual undifferentiated large cell variant of small cell lung carcinoma.
It has the morphology of a variant, but the biochemical properties of a classic SCLC.
Electron microscopy revealed the presence of gland formation and intracytoplasmic lamellar bodies.
The cells have neuroendocrine markers L-dopa decarboxylase and dense core secretory granules.
SHP-77 can serve as an in vitro target in 51Cr and 111In release cytotoxicity assays as well as in vivo nude mice assays for evaluating immune reactivity of cells and serum from lung cancer patients.
The cells can be used to evaluate the immune status of patients with SCLC who are treated with radiation or chemotherapy.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 3 to 4 days
Cultures can be maintained by addition or replacement of fresh medium.
Start cultures at 4 to 5 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
The cells grow as floating clusters with some loosely adherent cells, but only the floating cells are transferred.
Preservation: Culture medium, 95%; DMSO, 5%
Doubling Time: 96 hrs
Related Products: SHP-77細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
References: 21861: . Immune-deficient animals. Basel: Karger; 1984.
22751: . . J. Exp. Clin. Res. 4: 355-363, 1985.
22982: Fisher ER, et al. Comparative histopathologic, histochemical, electron microscopic and tissue culture studies of bronchial carcinoids and oat cell carcinomas of lung. Am. J. Clin. Pathol. 69: 165-172, 1978. PubMed: 204185
23055: Koros AM, et al. Stability and utility of the unique human small cell carcinoma line SHP-77. Cancer Res. 45: 2725-2731, 1985. PubMed: 2985251
23090: Carbone DP, et al. Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. Cancer Res. 51: 6142-6149, 1991. PubMed: 1718595
23372: Fisher ER, Paulson JD. A new in vitro cell line established from human large cell variant of oat cell lung cancer. Cancer Res. 38: 3830-3835, 1978. PubMed: 212181
23375: Koros AM, et al. 186Rhenium-HNK1 monoclonal antibody targets human small cell lung cancer cells in athymic nude mice: rapid screening model for therapy. Anticancer Res. 13: 1953-1956, 1993. PubMed: 7507652
24247: Koros. Monoclonal antibodies directed against small cell carcinomas define by flow cytometry phenotypic differences among small cell and non-small cell carcinomas, neuroblastomas, and lymphoblastoid cell lines. Lung Cancer 4: 52-54, 1988.
